Volume 8, Issue 3 (8-2021)
JROS 2021, 8(3): 163-170 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eulalia Landro M, Daffunchio C, Cambiaggi G, Galatro G, Honnorat E, Caviglia H. Comparative Analysis of Platelet-rich Plasma Treatment for Chronic Synovitis in Patients With Hemophilia: A Six-month Follow-up. JROS 2021; 8 (3) :163-170
URL: http://jros.iums.ac.ir/article-1-2173-en.html
URL: http://jros.iums.ac.ir/article-1-2173-en.html
Maria Eulalia Landro 
1, Carla Daffunchio1 , Guillermo Cambiaggi1 , Gustavo Galatro1 , Egle Honnorat2 , Horacio Caviglia1
1, Carla Daffunchio1 , Guillermo Cambiaggi1 , Gustavo Galatro1 , Egle Honnorat2 , Horacio Caviglia1
1- Department of Orthopaedic and Traumatology, General Hospital Juan A Fernández, Cerviño, CABA, Argentina.
2- Haemophilia Foundation, Soler, CABA, Argentina.
2- Haemophilia Foundation, Soler, CABA, Argentina.
Abstract: (930 Views)
Background: Inhibitor development is the main treatment-related complication in patients with hemophilia. Degenerative joint lesions caused by repeated bleeding episodes are more common in patients with inhibitors than in those without inhibitors. We introduced Platelet-rich Plasma (PRP) treatment to reduce joint damage and provide symptomatic relief.
Objectives: The aim of this study was to compare PRP treatment outcomes in two groups of patients with hemophilia presenting synovitis, with or without inhibitors, at 3- and 6-month follow-ups.
Methods: We treated 87 patients with 143 affected joints divided into two groups: 78 patients without inhibitors with 129 affected joints and a mean age of 25.8 years, and 9 patients with inhibitors with 14 affected joints and a mean age of 16.3 years.
Results: The difference in mean age between the two groups was statistically significant (P=0.007). The number of bleeding episodes, Visual Analogue Scale (VAS), and Hemophilia Joint Health Score (HJHS) before treatment and after three and six months showed no statistically significant differences between groups. We demonstrated that PRP treatment decreased the number of bleeding episodes, pain levels, and HJHS in the whole study population (P<0.001). No differences were found between patients with and without inhibitors.
Conclusion: PRP was proved to be effective for synovitis treatment in patients with hemophilia with and without inhibitors.
Objectives: The aim of this study was to compare PRP treatment outcomes in two groups of patients with hemophilia presenting synovitis, with or without inhibitors, at 3- and 6-month follow-ups.
Methods: We treated 87 patients with 143 affected joints divided into two groups: 78 patients without inhibitors with 129 affected joints and a mean age of 25.8 years, and 9 patients with inhibitors with 14 affected joints and a mean age of 16.3 years.
Results: The difference in mean age between the two groups was statistically significant (P=0.007). The number of bleeding episodes, Visual Analogue Scale (VAS), and Hemophilia Joint Health Score (HJHS) before treatment and after three and six months showed no statistically significant differences between groups. We demonstrated that PRP treatment decreased the number of bleeding episodes, pain levels, and HJHS in the whole study population (P<0.001). No differences were found between patients with and without inhibitors.
Conclusion: PRP was proved to be effective for synovitis treatment in patients with hemophilia with and without inhibitors.
Type of Study: Research Article |
Subject:
Trauma
Received: 2021/05/6 | Accepted: 2021/07/25 | Published: 2021/08/1
Received: 2021/05/6 | Accepted: 2021/07/25 | Published: 2021/08/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
